OBJECT: To overcome the problems associated with using stereotactic techniques to establish intracranial xenografts in nude mice and to treat engrafted tumors with intratumoral therapies (such as gene or viral therapies), the authors developed an implantable guide-screw system. In this study, they describe the guide-screw system, its method of implantation, and their experience with establishing xenografts and delivering intratumoral therapy. METHODS: The system consists of a 2.6-mm guide screw with a central 0.5-mm diameter hole that accepts the 26-gauge needle of a Hamilton syringe. The screw is implanted into a small drill hole made 2.5 mm lateral and 1 mm anterior to the bregma. A stylet is used to cap the screw between treatments. Tumor cells or therapeutic agents are injected in a freehand fashion by using a Hamilton syringe and a 26-gauge needle fitted with a cuff to determine the depth of injection. To test this system, guide screws were successfully implanted in 44 (98%) of 45 nude mice. After 1 to 2 weeks of recovery, 38 mice were inoculated with U87MG cells and killed 5 days later. On histological studies in 37 (97%) of these animals, xenografts were evident within the caudate nucleus (mean diameter 2.5 mm). To determine whether injections into the center of an established xenograft could be reproducibly achieved with the guide-screw system, an adenovirus vector containing the beta-galactosidase gene was injected 3 days after cell implantation in 15 of the mice. All of these animals demonstrated transduced cells within the tumor. To demonstrate that engrafted animals have a uniform survival time that is indicative of reproducible tumor growth, the survival of six mice was assessed after engraftment with U87MG cells. All six animals died within 28 to 35 days. CONCLUSIONS: The guide-screw system allows a large number of animals to be rapidly and reproducibly engrafted and for intratumoral treatments to be accurately delivered into established xenografts.
OBJECT: To overcome the problems associated with using stereotactic techniques to establish intracranial xenografts in nude mice and to treat engrafted tumors with intratumoral therapies (such as gene or viral therapies), the authors developed an implantable guide-screw system. In this study, they describe the guide-screw system, its method of implantation, and their experience with establishing xenografts and delivering intratumoral therapy. METHODS: The system consists of a 2.6-mm guide screw with a central 0.5-mm diameter hole that accepts the 26-gauge needle of a Hamilton syringe. The screw is implanted into a small drill hole made 2.5 mm lateral and 1 mm anterior to the bregma. A stylet is used to cap the screw between treatments. Tumor cells or therapeutic agents are injected in a freehand fashion by using a Hamilton syringe and a 26-gauge needle fitted with a cuff to determine the depth of injection. To test this system, guide screws were successfully implanted in 44 (98%) of 45 nude mice. After 1 to 2 weeks of recovery, 38 mice were inoculated with U87MG cells and killed 5 days later. On histological studies in 37 (97%) of these animals, xenografts were evident within the caudate nucleus (mean diameter 2.5 mm). To determine whether injections into the center of an established xenograft could be reproducibly achieved with the guide-screw system, an adenovirus vector containing the beta-galactosidase gene was injected 3 days after cell implantation in 15 of the mice. All of these animals demonstrated transduced cells within the tumor. To demonstrate that engrafted animals have a uniform survival time that is indicative of reproducible tumor growth, the survival of six mice was assessed after engraftment with U87MG cells. All six animals died within 28 to 35 days. CONCLUSIONS: The guide-screw system allows a large number of animals to be rapidly and reproducibly engrafted and for intratumoral treatments to be accurately delivered into established xenografts.
Authors: Yumi Watanabe; Sei Kameoka; Vidya Gopalakrishnan; Kenneth D Aldape; Zhizhong Z Pan; Frederick F Lang; Sadhan Majumder Journal: Genes Dev Date: 2004-04-12 Impact factor: 11.361
Authors: R Bonavia; M M Inda; S Vandenberg; S-Y Cheng; M Nagane; P Hadwiger; P Tan; D W Y Sah; W K Cavenee; F B Furnari Journal: Oncogene Date: 2011-12-05 Impact factor: 9.867
Authors: M H Lopes; T G Santos; B R Rodrigues; N Queiroz-Hazarbassanov; I W Cunha; A P Wasilewska-Sampaio; B Costa-Silva; F A Marchi; L F Bleggi-Torres; P I Sanematsu; S H Suzuki; S M Oba-Shinjo; S K N Marie; E Toulmin; A F Hill; V R Martins Journal: Oncogene Date: 2014-08-25 Impact factor: 9.867
Authors: Fernanda I Staquicini; Michael G Ozawa; Catherine A Moya; Wouter H P Driessen; E Magda Barbu; Hiroyuki Nishimori; Suren Soghomonyan; Leo G Flores; Xiaowen Liang; Vincenzo Paolillo; Mian M Alauddin; James P Basilion; Frank B Furnari; Oliver Bogler; Frederick F Lang; Kenneth D Aldape; Gregory N Fuller; Magnus Höök; Juri G Gelovani; Richard L Sidman; Webster K Cavenee; Renata Pasqualini; Wadih Arap Journal: J Clin Invest Date: 2010-12-22 Impact factor: 14.808
Authors: Dimpy Koul; Jun Fu; Ruijun Shen; Tiffany A LaFortune; Shuzhen Wang; Ningyi Tiao; Yong-Wan Kim; Juinn-Lin Liu; Deepti Ramnarian; Ying Yuan; Carlos Garcia-Echevrria; Sauveur-Michel Maira; W K Alfred Yung Journal: Clin Cancer Res Date: 2011-11-07 Impact factor: 12.531
Authors: Ok-Hee Lee; Juan Fueyo; Jing Xu; W K Alfred Yung; Michael G Lemoine; Frederick F Lang; B Nebiyou Bekele; Xian Zhou; Marta A Alonso; Kenneth D Aldape; Gregory N Fuller; Candelaria Gomez-Manzano Journal: Neoplasia Date: 2006-05 Impact factor: 5.715